Back to results
US 9,528,102 B2Granted
Proteoglycan degrading mutants for treatment of CNS
AssigneeAcorda Therapeutics, Inc.
InventorsElliott A. Gruskin, Rohini D'Souza, Gargi Roy, Anthony O. Caggiano
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease.
Claims6
An isolated nucleic acid comprising a cDNA sequence that encodes for a mutant polypeptide of chondroitinase ABC I,
- wherein the mutant polypeptide is selected from SEQ ID NO:
- 2, SEQ ID NO:
- 3 or SEQ ID NO:
- 4.
1 more element
Dependencies are inferred from the claim text.